+2155683439 From-WoodcockWa

ISIS-0710

02:35pm

Jul-19-05

PETITION TO WITHDRAW FROM ISSUE UNDER 37 CFR 1.313(c)(1)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cook et al.

**FAX RECEIVED** 

Serial No.: 07/967,267

Group Art Unit: 1623

Filed: October 27, 1992

Examiner: Howard Owens

JUL 1 9 2005

For:

OFFICE OF PETITIONS

Oligonucleotides Containing 2'-O-Modified Purines

CERTIFICATE OF FACSIMILE TRANSMISSION

July 19, 2005 DATE OF DEPOSIT:\_\_\_

I HEREBY CERTIFY THAT THIS PAPER IS BEING FACSIMILE TRANSMITTED TO THE PATENT AND TRADEMARK OFFICE TO FACSIMILE NUMBER 571-273-0025 ON THE DATE LISTED ABOVE

TYPED NAME: Joffrey H. Rosedale REGISTRATION NO.: 46,018

Office of Petitions MAILSTOP 313C Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

### PETITION TO WITHDRAW FROM ISSUE UNDER 37 C.F.R. § 1.313(c)(1)

Applicants respectfully request that the above-identified patent application be withdrawn from issue after payment of the issue fee, pursuant to 37 C.F.R. § 1.313(c)(1). This petition is being accompanied with:

- a) an unequivocal statement that one or more claims are unpatentable;
- b) an amendment to such claim or claims;
- c) an explanation as to how the amendment causes such claim or claims to be patentable;
- d) a showing of good and sufficient reasons why withdrawal of the application from issue is necessary; and
- e) the fee set forth in 37 CFR 1.17(h), large entity, for this petition.

Jul-19-05

ISIS-0710

PETITION TO WITHDRAW FROM ISSUE UNDER 37 CFR 1.313(c)(1)

## Unequivocal Statement that One or More Claims are Unpatentable

Applicants respectfully submit that allowed claims 9 and 20 are unpatentable under 35 U.S.C. §102(b) in view of Inoue, et al., "Studies on the recognition mode of E.col RNuse H using modified oligonucleotide probes", Nucleic Acids Research, 1988, Symposium Series No. 20, 9-10 ("the Inoue reference"). A copy of the Inoue reference and an Information Disclosure Statement directed to it accompany this petition.

#### Amendment to the Claims

Enclosed herewith is a new listing of allowed claims 9, 10, and 15-27 showing amendments to claims 9 and 20.

## Explanation as to How the Amendment Causes Claims 1 and 20 to be Patentable

The Inoue reference, page 10, discloses oligonucleotides containing guanine-based nucleotides modified with 2'-O-methoxymethyl groups (compounds V and VI containing Gm' groups). In claims 1 and 20, as amended, R1 does not include 2'-O-methoxymethyl groups.

### Showing of Good and Sufficient Reasons Why Withdrawal of the Application from Issue is Necessary

Although the issue fee was paid September 18, 2003, Applicants only recently became aware of the Inoue reference. Withdrawal of the application from issue is necessary because allowed claims 1 and 20 are unpatentable under 35 U.S.C. §102(b) in view of the Inoue reference for the reasons described above.

### Fee Set Forth in 37 CFR 1.17(h) for this Petition

Please charge the \$130.00 fee to Deposit Account #23-3050.

Applicants respectfully request granting of this petition, consideration of the Information Disclosure Statement, entering of the amendment, and a prompt notice of allowance. Please charge any additional fees or deposit any refunds to Deposit Account # 23-3050.

From-WoodcockW

ISIS-0710

**PETITION TO** WITHDRAW FROM ISSUE UNDER 37 CFR 1.313(c)(1)

If there are any questions or concerns, the office is urgently requested to telephone Applicant's attorney at the number listed below.

Respectfully submitted,

Jeffrey H. Rosedale Attorney for Applicants Registration No. 46,018

Date: July 19, 2005

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor

Philadelphia, PA 19103

Telephone

(215) 568-3100

Facsimile

(215) 568-3439